Predicting chemotherapy response in bladder cancer patients
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
This study is trying to see if looking at the genes and molecules in bladder cancer patients can help figure out who will respond well to chemotherapy and who might need different treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Yonsei University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06373055 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify which patients with muscle-invasive bladder cancer will respond effectively to neoadjuvant chemotherapy. By analyzing the genetic and molecular profiles of patients scheduled for this treatment, the study seeks to differentiate between those who will benefit from chemotherapy and those who may require alternative treatments, such as radical cystectomy. The goal is to tailor treatment plans to improve patient outcomes and reduce unnecessary treatment toxicity and delays.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are suspected of having bladder cancer and are scheduled for transurethral resection of bladder tumor.
Not a fit: Patients who do not agree to participate in the study or are considered vulnerable may not receive any benefit.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment plans, improving outcomes for bladder cancer patients.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in predicting treatment responses in other cancers, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Suspicious of bladder cancer scheduled to have transurethral resection of bladder tumor * Consent to the provision of their biospecimen. * Willing to cooperate with this study and comply with the restrictions. * Voluntarily signed the consent form for participation in the study. * Age ≥18. Exclusion criteria: * Do not agree with this study. * Vulnerable participants
Where this trial is running
Seoul
- Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Won Sik Ham — Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea
- Study coordinator: Won Sik Ham
- Email: uroham@yuhs.ac
- Phone: 02-2228-2310
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.